DadFinStart your free week
DadFin › Stocks › Healthcare › QGEN

Qiagen N.V. (QGEN) stock score

Healthcare · Diagnostics & Research · Netherlands

$45.38 ▲ +1.91% today

98.7
Dad Score, out of 100
strong

Qiagen N.V. (QGEN) is a Diagnostics & Research company in the Healthcare sector, listed in the Netherlands. On DadFin's weekly run it scores 98.7 out of 100 on the Dad Score, a strong reading that places the business ahead of 99% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #14 of 974. Its strongest axes are valuation, quality and growth; its weakest is conviction.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Strong
Quality
Above average
Growth
Strong
Price action
Strong
Risk
Average
Conviction
Weak
Liquidity
Strong
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)22.7×
P/E (forward)17.1×
Dividend yield0.86%
Return on capital9.1%
Operating margin26.3%
Revenue growth (YoY)+5.7%
FCF yield4.4%
Net debt / EBITDA1.17×
Piotroski F-Score6 / 9
52-week change-3.8%
Market cap$9.2B
Next earningsNov 4, 2026

What subscribers see on QGEN

Start your free weekSubscriber? Open the full research →

Diagnostics & Research peers

StockCompanyDad ScoreBandMarket cap
TMOThermo Fisher Scientific Inc.77.0good$242.1B
DHRDanaher Corporation79.6good$150.5B
NTRANatera, Inc.86.1strong$59.1B
AAgilent Technologies, Inc.79.9good$47.3B
IQVIQVIA Holdings Inc.82.3good$42.5B
WATWaters Corporation78.8good$41.7B
ILMNIllumina, Inc.35.1weak$41.2B
IDXXIDEXX Laboratories, Inc.90.1strong$40.9B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.